Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $16.70.
A number of research firms have commented on CLBT. Lake Street Capital reduced their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Weiss Ratings downgraded shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 27th. DA Davidson reissued a “buy” rating and set a $15.00 price target on shares of Cellebrite DI in a research note on Tuesday, September 15th. Needham & Company LLC lowered their price target on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. dropped their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 14th.
Check Out Our Latest Research Report on Cellebrite DI
Cellebrite DI Trading Up 1.1%
Shares of CLBT stock opened at $12.23 on Tuesday. Cellebrite DI has a 12-month low of $9.58 and a 12-month high of $19.98. The company has a market cap of $3.05 billion, a price-to-earnings ratio of 43.21, a price-to-earnings-growth ratio of 1.85 and a beta of 1.14. The stock has a 50 day simple moving average of $11.39 and a 200-day simple moving average of $13.60.
Insider Buying and Selling at Cellebrite DI
In other Cellebrite DI news, insider Thomas E. Hogan sold 25,299 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total transaction of $285,625.71. Following the completion of the transaction, the insider directly owned 765,249 shares in the company, valued at approximately $8,639,661.21. This trade represents a 3.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO David Barter sold 12,134 shares of Cellebrite DI stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $11.21, for a total transaction of $136,022.14. Following the transaction, the chief financial officer owned 322,085 shares of the company’s stock, valued at approximately $3,610,572.85. The trade was a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 196,870 shares of company stock valued at $2,797,143 over the last 90 days. 5.70% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Elevation Wealth Partners LLC purchased a new stake in Cellebrite DI in the 2nd quarter valued at approximately $44,000. PNC Financial Services Group Inc. increased its position in Cellebrite DI by 59.6% during the first quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company’s stock worth $103,000 after buying an additional 2,785 shares in the last quarter. Pacer Advisors Inc. increased its position in Cellebrite DI by 91.1% during the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock worth $105,000 after buying an additional 3,626 shares in the last quarter. Quantinno Capital Management LP purchased a new position in Cellebrite DI during the first quarter worth $150,000. Finally, Harmony Asset Management LLC acquired a new position in shares of Cellebrite DI in the first quarter worth $200,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Cellebrite DI Company Profile
Cellebrite DI Ltd. (NASDAQ: CLBT) provides digital intelligence and digital forensics solutions that help organizations collect, preserve, analyze and manage data from mobile devices, computers, cloud environments and other digital sources. Its customers include law enforcement agencies, public safety organizations, government and intelligence bodies, military units, and corporate security and investigation teams.
The company’s offerings include tools for accessing and extracting digital evidence, case and evidence management, and investigative analytics.
Further Reading
- Five stocks we like better than Cellebrite DI
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
